MarlynJean(Krampitz)MayoMD
Gastroenterology • Dallas, TXHepatology & Liver Transplantation
Professor of Medicine, University Tex SW Dallas
Dr. Mayo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-0595Fax+1 214-645-0596- Is this information wrong?
Education & Training
University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 1993 - 1996
University of California (Irvine)Residency, Internal Medicine, 1990 - 1993
Baylor College of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1992 - Present
TX State Medical License 1992 - 2024- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (AGAF) American Gastroenterological Association, 2011
Clinical Trials
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- Systemic Complications of Primary Biliary Cholangitis.Mariana Zapata, Hendrick Pagan-Torres, Marlyn J Mayo> ;Clinics in Liver Disease. 2024 Feb 1
- Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply.Mayo, M., Vierling, J., Bowlus, C.> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
- 2 citationsOpen-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield, Guy W Neff, Michael R Galambos, Stuart C Gordon, Brian B Borg, Stephen A Harr...> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
- Join now to see all
Journal Articles
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver DiseasesMarlyn (Krampitz) Mayo, MD, Hepatology
Authored Content
- The Liver Meeting's Highlights and LowlightsNovember 2023
Press Mentions
Study Outlines Risk Factors for Autoimmune Hepatitis After Liver TransplantMay 20th, 2022- CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary CholangitisNovember 11th, 2021
- CymaBay Therapeutics Inc. (CBAY) Q3 2021 Earnings Call TranscriptNovember 10th, 2021
- Join now to see all
Grant Support
- Ursodeoxycholic Acid (UDCA) In Primary Biliary CirrhosisNational Center For Research Resources2007
- UDCA Amp;Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2007
- Treatment Of Metabolic PruritisNational Center For Research Resources2004–2007
- UDCA &Methotrexate For Primary Biliary CirrhosisNational Center For Research Resources2006
- Longitudinal Studies Of Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
- 1treatment Of Cholestatic Pruritus With SertralineNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Role Of CD40-CD40 Ligand In Primary Biliary CirrhosisNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2003
- Role Of CD40 Ligand In Primary Biliary CirrhosisNational Center For Research Resources1998–2002
Committees
- Member, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) 2016 - Present
Professional Memberships
- Fellow
Hospital Affiliations
University of Texas Southwestern Medical CenterDallas, Texas
Parkland HealthDallas, Texas
William P. Clements, Jr. University HospitalDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
